



Digital Health

Digital health technologies have emerged as powerful tools to help connect patients with vital care while limiting in-person interactions. The coronavirus disease 2019 (COVID-19) pandemic triggered a seismic shift in the industry, shaping how technology and healthcare services are delivered, with decades' worth of changes happening seemingly overnight.

Our approach

DLA Piper can help. Our knowledgeable lawyers understand the digital health environment, its nuances and its complexities. We have in-depth experience advising businesses tackling issues in AI, telehealth and telemedicine, digital therapeutics, apps and wearable technology, health IT, big data, cybersecurity and privacy. We work as a multi-disciplinary team, considering obstacles and opportunities holistically through the collaboration of our healthcare and life sciences regulatory, cybersecurity, privacy, litigation, corporate and intellectual property lawyers.

Our team of thought leaders in the areas of digital health laws and compliance risks routinely partners with industry associations to advise on policies. We have helped to create regional, national and global telehealth networks and have assisted numerous US and global clients with the integration of AI and machine learning software for use with their medical devices and pharmaceutical products. We help startups at every stage to position themselves for funding via venture capital and other financing, structure corporate and commercial partnerships in the digital health environment, including arrangements to commercialize data, and explore and execute IPO and M&A exit strategies.

Our innovative, thoughtful approach draws on our experience across the globe and across specialties. We are a collaborative group, partnering with our clients to gain a better understanding of their issues and goals and to help them redefine the standard of care and the future of healthcare. For those in the digital health space, we are a one-stop shop, drawing on our multidisciplinary, global network and our vast experience across the spectrum of business law to provide sound, practical and customized legal advice. Let us put our experience to work for you.

RELATED SECTORS

- Healthcare
- Life Sciences

Publikationen

The rise of global telehealth

30 June 2022

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

Partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address disparate access to healthcare globally.

Telehealth's impact on low-income communities

24 January 2022

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

Shared from our Beyond the Curve podcast series

Ray Williams and Kirsten Axelsen are joined by Dr. Benson Hsu of the University of South Dakota Sanford School of Medicine for a frank discussion on disparities to engaging with telehealth and ways to better serve low income communities. Originally recorded on March 3, 2021.

The Hidden Cost of Price Control Policies with Kirsten Axelsen

15 September 2021

An interview with Kirsten Axelsen about what would change in biopharma if price controls were implemented.

SEMINARE UND VERANSTALTUNGEN

Vergangene

2022 Health Datapalooza and National Health Policy Conference

5 April 2022 | 10:45 ET
Webseminare

2021 Healthcare Leadership Conference: Day 4 - Path to restructuring and recovery

11 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

2021 Healthcare Leadership Conference: Day 3 - Washington roundtable

10 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

2021 Healthcare Leadership Conference: Day 2 - Unlocking innovation and collaboration through digital health and technology

9 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

2021 Healthcare Leadership Conference: Day 1 - The dealmakers, the visionaries and the advocates

8 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

How technology is impacting healthcare delivery in a COVID-19 world

13 January 2021 | 1:00 - 2:00 EST

Webinar

NEWS

DLA Piper partner John Gibson named to the *Daily Journals* 2022 Top Antitrust Lawyers list

17 November 2022

DLA Piper is pleased to announce that partner John Gibson was named to the *Daily Journals* 2022 Top Antitrust Lawyers list honoring the top attorneys across the state of California who have made significant contributions in antitrust law. This marks his second consecutive year on the prestigious list.

DLA Piper partner Kristi Kung named a DC Rising Star by the *National Law Journal*

17 November 2022

DLA Piper is pleased to announce that partner Kristi Kung has been named a 2022 DC Rising Star by the *National Law Journal*.

DLA Piper advises Brookline Capital Acquisition Corp. in the closing of its business combination with Apexigen, Inc.

2 August 2022

DLA Piper advised Brookline Capital Acquisition Corp., a special purpose acquisition company, in the closing of its business combination with Apexigen, Inc., a clinical-stage biopharmaceutical company. The combined, publicly traded company will operate under the name Apexigen, and its common stock commenced trading on the Nasdaq Capital Market on August 1, 2022 under the ticker symbol "APGN."

DLA Piper lawyers and practices ranked in latest edition of *The Legal 500*

15 June 2022

DLA Piper announced today that the firm received 52 firm rankings and 273 lawyers were featured in *The Legal 500 United States 2022* guide.

DLA Piper partner Jessica Wilson named a *Law360* Life Sciences Rising Star

14 June 2022

DLA Piper is pleased to announce that partner Jessica Wilson has been named a 2022 *Law360* Life Sciences Rising Star.

DLA Piper continues expansion of its Regulatory and Government Affairs practice with David Kopans in Washington, DC

6 May 2022

DLA Piper has added nationally regarded healthcare regulatory partner David Kopans in its Washington, DC office.

Bethany Hills joins DLA Piper's FDA Regulatory practice in New York

3 May 2022

DLA Piper continues the growth of its FDA Regulatory group with the arrival of Bethany Hills as a partner in the firm's New York office. Hills will join as vice chair of the FDA practice, working with co-chairs Geoff Levitt and Stefanie Fogel to support their rapid expansion of DLA Piper's FDA regulatory capabilities.

DLA Piper named a top three law firm for private equity deal volume by *PitchBook*

8 March 2022

DLA Piper is pleased to announce that the firm ranked among the top three most active law firms for global private equity deal volume in the past year, according to *PitchBook's* 2021 global league tables report.

DLA Piper advises mPulse Mobile in growth investment from PSG

20 January 2022

DLA Piper represented mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, in a growth investment from PSG, a leading growth equity firm partnering with middle-market software and technology-enabled services companies.

Christopher Halliday joins DLA Piper's Patent Prosecution practice and Life Sciences sector in Philadelphia

18 January 2022

DLA Piper announced today that Christopher Halliday has joined the firm's Patent Prosecution practice and Life Sciences sector as a partner in Philadelphia.

DLA Piper advises Pack4U in its acquisition of Catalyst Healthcare

18 January 2022

DLA Piper represented Pack4U, a connected health services company, in its acquisition of leading pharmacy technology company Catalyst Healthcare.

DLA Piper joins with Duke, Mayo Clinic, UC Berkeley to launch innovative AI collaboration

21 December 2021

DLA Piper has joined with the Duke Institute for Health Innovation, the Mayo Clinic and UC Berkeley, among others, to launch an innovative collaboration designed to build an understanding of the AI software market and allow for its safe and responsible deployment, including of machine learning algorithms.

Campos Mello Advogados announces four new partners

8 December 2021

DLA Piper announced today the addition of four new partners at Campos Mello Advogados (CMA), which has a cooperation agreement with DLA Piper.

DLA Piper partners Jeff Baglio and Erin Gibson named to *San Diego Business Journal's* 2021 Leaders in Law list

15 November 2021

DLA Piper is pleased to announce that partners Jeff Baglio and Erin Gibson have been named to the *San Diego Business Journals* 2021 Leaders in Law list.

Ardith Bronson, Isabel De Obaldia and Rebecca Jones McKnight named to *The American Lawyer's* list of 2021 South Trailblazers

4 October 2021

DLA Piper is pleased to announce that Ardith Bronson, Irma Isabel De Obaldia and Rebecca Jones McKnight have been named to *The American Lawyer's* inaugural list of South Trailblazers. The list recognizes professionals in the South "who have moved the needle in the legal industry."

DLA Piper partner Jeff Baglio named a 2021 BTI M&A Client Service All-Star

9 September 2021

DLA Piper is pleased to announce that BTI Consulting Group has recognized partner Jeff Baglio for providing superior service to clients in its 2021 BTI M&A Client Service All-Star report.

DLA Piper achieves appellate victory for AMN Healthcare in antitrust lawsuit

24 August 2021

DLA Piper recently won a significant appellate victory on behalf of AMN Healthcare defeating a lawsuit seeking more than US\$50 million in damages that alleged violations of federal and state antitrust laws.

Deborah Samenow joins DLA Piper's Healthcare sector in Washington, DC

9 August 2021

DLA Piper announced today that Deborah Samenow has joined the firm's Litigation and Regulatory practice and Healthcare sector as of counsel based in Washington, DC.

DLA Piper advises underwriters of MaxCyte's upsized US IPO

30 July 2021

DLA Piper represented Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C., as underwriters in the initial US public offering of 13,500,000 shares of common stock of MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, at an initial offering price of US\$13.00 per share.

DLA Piper recognized as one of the "Most Recommended Law Firms" by BTI Consulting Group

26 July 2021

Due to its ability to "exceed client expectations and consistently demonstrate deep business understanding," DLA Piper is pleased to announce that it has been named one of the 11 Most Recommended Law Firms by BTI Consulting Group for 2021.

DLA Piper advises Abry Partners in US\$400 million sale of Sentry Data Systems

16 July 2021

DLA Piper represented private equity investment firm Abry Partners in its US\$400 million sale of Sentry Data Systems, Inc.

DLA Piper advises Lionheart Acquisition Corp. II in US\$32.6 billion SPAC deal with MSP Recovery

13 July 2021

DLA Piper represented special purpose acquisition company (SPAC) Lionheart Acquisition Corp. II. in its agreement to merge with MSP Recovery LLC.

DLA Piper advises FastMed in its acquisition of CareSpot and MedPost Urgent Care

12 July 2021

DLA Piper represented FastMed in its recent acquisition of Tenet Healthcare's urgent care platform, which includes 87 CareSpot and MedPost clinics in Arizona, California, Florida and Texas.

DLA Piper advises emocha Health in US\$6.2 million Series A financing

7 July 2021

DLA Piper represented emocha Health in its recently completed US\$6.2 million Series A financing.

DLA Piper lawyers and practices ranked in latest edition of *The Legal 500*

17 June 2021

DLA Piper announced today that the firm received 42 individual lawyer rankings and 49 firm rankings in *The Legal 500 United States 2021* guide.

DLA Piper advises CareMax in business combination with Deerfield Healthcare Technology Acquisitions Corp.

18 June 2021

DLA Piper represented CareMax Medical Group, L.L.C. in its business combination, along with IMC Medical Group Holdings LLC, with special purpose acquisition company Deerfield Healthcare Technology Acquisitions Corp. to create a publicly traded technology-enabled care platform providing value-based care and chronic disease management to seniors.

DLA Piper advises Harrison Street on US\$1.6 billion medical office and senior housing transactions

17 June 2021

DLA Piper advised Harrison Street on an integrated series of transactions through which Harrison Street agreed to purchase 24 senior housing assets and sell 14 medical office properties across eight states over numerous months for a total transaction value of approximately US\$1.6 billion.

DLA Piper lawyers and practices ranked in latest Chambers edition

1 June 2021

DLA Piper today announced that the firm received 216 lawyer rankings and 94 firm rankings in *Chambers USA's 2021* guide.

Tracy Weir joins DLA Piper's Litigation and Regulatory practice and Healthcare sector in Washington, DC

17 May 2021

DLA Piper announced today that Tracy Weir has joined the firm's Litigation and Regulatory practice and Healthcare sector as a partner based in Washington, DC.

DLA Piper advises Denali Growth Partners in closing of US\$203 million growth equity fund

30 March 2021

DLA Piper represented Denali Growth Partners in the close of its US\$203 million inaugural fund, Denali Growth Partners Fund I, L.P.

DLA Piper advises ICV Partners in control investments in Total Access Urgent Care and Cherry Tree Dental

25 March 2021

DLA Piper represented ICV Partners, LLC in its control investments in Total Access Urgent Care (TAUC) and Cherry Tree Dental.

DLA Piper advises Truvian Sciences in oversubscribed US\$105 million Series C financing

24 February 2021

DLA Piper represented Truvian Sciences in its recent oversubscribed US\$105 million Series C financing.

DLA Piper advises EQ Health Acquisition Corp. in its upsized US\$220 million initial public offering

11 February 2021

DLA Piper represented EQ Health Acquisition Corp. in its recent upsized initial public offering of 21,999,960 units at a price of \$10 per unit.

DLA Piper advises Sidecar Health in US\$125 million Series C financing

3 February 2021

DLA Piper represented health insurtech company Sidecar Health in its recent US\$125 million Series C financing, resulting in its subsequent valuation at US\$1 billion.

DLA Piper advises Unseen Capital Health Fund in US\$30 million investment from Eli Lilly and Company

25 January 2021

DLA Piper represented Unseen Capital Health Fund LP in a recent US\$30 million limited partner investment from global pharmaceutical company Eli Lilly and Company.

DLA Piper advises Stifel in Tastemaker Acquisition Corp.'s US\$276 million IPO and advises Stifel and Nomura in OCA Acquisition Corp.'s US\$149.5 million IPO

21 January 2021

DLA Piper represented Stifel as sole book-running manager of the US\$276 million initial public offering by Tastemaker Acquisition Corp., a special purpose acquisition company (SPAC) focused on the restaurant, hospitality, and related technology and service sectors globally.

The *Financial Times* ranks DLA Piper second Most Innovative and second Most Digital law firm in 2020 North America Innovative Lawyers report

16 December 2020

DLA Piper is pleased to announce it was ranked second by the *Financial Times* for both the Most Innovative and Most Digital law firm in the FT North America Innovative Lawyers 2020 report.

DLA Piper shortlisted by the *Financial Times* for five FT North America Innovative Lawyers awards

8 December 2020

DLA Piper is pleased to announce it has been shortlisted by the *Financial Times* for five FT North America Innovative Lawyers 2020 awards.
